|Mr. Paul Hudson||CEO & Director||N/A||N/A||1967|
|Mr. Jean-Baptiste Chasseloup de Chatillon||Exec. VP & CFO||N/A||N/A||1965|
|Mr. Laurent Gilhodes||Principal Accounting Officer and VP of Corp. Accounting||N/A||N/A||N/A|
|Mr. Bruno Ménard||Chief Information officer||N/A||N/A||N/A|
|Mr. George Grofik||Head of Investor Relations||N/A||N/A||N/A|
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, for hematologic malignancies; and Zaltrap, for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has an alliance with Verily Life Sciences LLC; and agreement with Happify Health. Sanofi was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Sanofi’s ISS Governance QualityScore as of October 4, 2019 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 4; Compensation: 2.